Assay kits are used to carry out analyses in a broad scope of applications including the study of targets such as drugs, molecules, disease pathways, chemical elements or compounds, and organisms. They are a routine procedure in the modern pharmaceutical, medical and forensic world as well as research and university laboratories around the globe. Assay kits come with all the necessary reagents, instructions and protocols for fast and efficient processing, allowing for repeatable results.
|  | | | | |
| Company | FUJIFILM Wako Chemicals U.S.A. Corporation | FUJIFILM Wako Chemicals U.S.A. Corporation | FUJIFILM Wako Chemicals U.S.A. Corporation | FUJIFILM Wako Chemicals U.S.A. Corporation | FUJIFILM Wako Chemicals U.S.A. Corporation |
| Item | Human beta-Amyloid (1-42) ELISA | Human/Rat beta-Amyloid (40) ELISA Kit II | Human/Rat beta-Amyloid (42) ELISA Kit | LabAssay Creatinine ELISA | Mature BDNF ELISA Kit Wako, High Sensitivity |
| Citations | | | | | |
| Catalog Number | 298-62401 | 294-64701 | 290-62601 | 636-51011 | 298-83901 |
| Price | Supplier Page | Supplier Page | Supplier Page | Supplier Page | Supplier Page |
| Description | Alzheimer's Disease (AD) is characterized by the presence of extracellular senile plaques (SPs) and intracellular neurofibrillary tangles (NFT) in the brain. The major protein component of SPs is beta Amyloid peptide (AB) 40 AND 42(43). AB 42 is more prone to aggregate than AB 40. Therefore the Alzheimer's Disease (AD) is characterized by the presence of extracellular senile plaques (SPs) and intracellular neurofibrillary tangles (NFT) in the brain. The major protein component of SPs is beta Amyloid peptide (AB) 40 AND 42(43). AB 42 is more prone to aggregate than AB 40. Therefore the initial AB deposition begins with AB 42(43) but not with AB 40. AB 42(43)-positive and AB 40-negative plaques may represent early-stage diffuse type SPs, and AB 40-positive plaque appears in the advanced stage, especially more often in the cored portion of the mature plaque.... Read More | Alzheimer's Disease (AD) is characterized by the presence of extracellular senile plaques (SPs) and intracellular neurofibrillary tangles (NFT) in the brain. The major protein component of SPs is beta Amyloid peptide (AB) 40 AND 42(43). AB 42 is more prone to aggregate than AB 40. Therefore the Alzheimer's Disease (AD) is characterized by the presence of extracellular senile plaques (SPs) and intracellular neurofibrillary tangles (NFT) in the brain. The major protein component of SPs is beta Amyloid peptide (AB) 40 AND 42(43). AB 42 is more prone to aggregate than AB 40. Therefore the initial AB deposition begins with AB 42(43) but not with AB 40. AB 42(43)-positive and AB 40-negative plaques may represent early-stage diffuse type SPs, and AB 40-positive plaque appears in the advanced stage, especially more often in the cored portion of the mature plaque.The improved (II) kits achieve more stable antigen-antibody reaction by using F(ab')2 fragment of the labeled antibody BA27, which recognizes the C-terminal of AB40, while the nonspecific binding is reduced. Therefore, the stability in the washing solution is improved and background is reduced.... Read More | Alzheimer's Disease (AD) is characterized by the presence of extracellular senile plaques (SPs) and intracellular neurofibrillary tangles (NFT) in the brain. The major protein component of SPs is beta Amyloid peptide (AB) 40 AND 42(43). AB 42 is more prone to aggregate than AB 40. Therefore the Alzheimer's Disease (AD) is characterized by the presence of extracellular senile plaques (SPs) and intracellular neurofibrillary tangles (NFT) in the brain. The major protein component of SPs is beta Amyloid peptide (AB) 40 AND 42(43). AB 42 is more prone to aggregate than AB 40. Therefore the initial AB deposition begins with AB 42(43) but not with AB 40. AB 42(43)-positive and AB 40-negative plaques may represent early-stage diffuse type SPs, and AB 40-positive plaque appears in the advanced stage, especially more often in the cored portion of the mature plaque.... Read More | Jaffé method | Inquire |
| Detection Target | Amyloid Beta | beta-Amyloid, aa 1-40 | Amyloid beta (Amyloid-b), aa 1-42 | Creatinine | Inquire |
| Sample Type | Inquire | Inquire | Inquire | Inquire | Inquire |
| Method | Enzyme-Linked Immunosorbent Assay (ELISA) | ELISA II | ELISA | Enzyme-Linked Immunosorbent Assay (ELISA) | Inquire |
| Detection Range | 1.0 to 100 (pM) | Inquire | Inquire | Inquire | Inquire |
| Sensitivity | 0.08 (pM) | Inquire | 0.19 (pM) | Inquire | Inquire |
| Assay Time | Inquire | Inquire | Inquire | Inquire | Inquire |
| Get Quote | Supplier Page | Supplier Page | Supplier Page | Supplier Page | Supplier Page |